about bpl

Bio Products Laboratory Ltd.

News

PRESS RELEASE: FDA Approves US Gammaplex 10%

 8 February 2017 -   FDA Approves Bio Products Laboratory's Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, today announced that the U.S. Food and Drug Administration (FDA) has ...

Date added: Wednesday 8th February 2017

PRESS RELEASE: Creat Group Corporation Completes Acquisition of Bio Products Laboratory Ltd

Elstree, 1 August, 2016 - Bio Products Laboratory Ltd. ("BPL"), a leading plasma biotherapeutics company, today announces that a group controlled by Creat Group Corporation ("Creat"), has finalized the acquisition of BPL.  BPL, headquartered in Elstree, Hertfordshire, provides lifesaving therapeutics for conditions related to immune deficiencies, ...

Date added: Tuesday 2nd August 2016
Latest updated: Wednesday 8th February 2017

PRESS RELEASE - 6 June 2016: Bio Products Laboratory launches Coagadex® ▼ (human coagulation factor X) in the UK Treatment for rare bleeding disorder ‘hereditary factor X deficiency’ and is made available in the UK

ELSTREE, UK Bio Products Laboratory, Limited (BPL) today, announced that Coagadex is now available for patients in the UK. Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is the ...

Date added: Monday 6th June 2016
Latest updated: Wednesday 8th February 2017

PRESS RELEASE: Creat Group Corporation agrees to acquire Bio Products Laboratory Ltd.

Elstree, 19 May, 2016 – Bio Products Laboratory Ltd. (“BPL”), a leading plasma biotherapeutics company, today announces that a group controlled by Creat Group Corporation (“Creat”), has signed a definitive agreement to acquire the company for a total cash consideration of £820 million. BPL, headquartered in ...

Date added: Thursday 19th May 2016
Latest updated: Wednesday 8th February 2017

PRESS RELEASE: Bio Products Laboratory Receives European Approval for Coagadex® ▼ (Human Coagulation Factor X) First-ever treatment for rare bleeding disorder ‘hereditary factor X deficiency'

NEWS RELEASE: March 17 th 2016     ELSTREE, UK Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex. Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for ...

Date added: Thursday 17th March 2016
Latest updated: Wednesday 8th February 2017

PRESS RELEASE - Gammaplex Approved For Use in Pediatric Patients

Gammaplex © Approved For Use In Pediatric Patients Gammaplex [Immune Globulin Intravenous (Human) 5% Liquid] Approved in Patients 2 years and Older with  Primary Immunodeficiencies ELSTREE, UK AND DURHAM, NC - August 6, 2015 - Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein ...

Date added: Thursday 6th August 2015
Latest updated: Wednesday 8th February 2017

FDA Accepts BPLs Amended BLA Submission for Coagadex (Coagulation Factor X, Human)

ELSTREE, UK AND DURHAM, NC - May 27, 2015 – Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s amended Biologics License Application for Coagadex® for hereditary ...

Date added: Friday 29th May 2015
Latest updated: Wednesday 8th February 2017

PRESS RELEASE - Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product

ELSTREE, UK AND DURHAM, NC - April 17, 2015 - Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived protein therapies, today announced the results from a phase III registration study examining the pharmacokinetics, efficacy, and safety of its FACTOR X coagulation product in ...

Date added: Monday 27th April 2015
Latest updated: Wednesday 8th February 2017

PRESS RELEASE - John Perkins to become new CEO BPL Holdings

LONDON, April 30, 2014 - BPL (Bio Products Laboratory) Holdings, a global biotherapeutics company, today announced that Kim Bjoernstrup has decided to step down from his role as Chief Executive Officer.  Mr. Bjoernstrup will continue as an advisor to the company.  John Perkins will become ...

Date added: Wednesday 30th April 2014
Latest updated: Wednesday 8th February 2017

BPL donates Replenine-VF to help Syrian refugee

Bio Products Laboratory is pleased to announce that, in conjunction with its local partner, Munir Sukhtian Group Co., a donation of Replenine-VF (Factor IX concentrate) has been made through the Syrian relief charity, Help Syrians, to provide life-saving treatment for Zaid, a teenage boy affected ...

Date added: Tuesday 25th March 2014
Latest updated: Wednesday 8th February 2017

Patient information leaflets